PROCEPT BioRobotics: The Lawsuit Is About Last Year. The Business Has Already Moved On.

A class action lawsuit has investors focused on a headline that tells them almost nothing about whether PROCEPT BioRobotics stock is worth owning today. The complaint alleges the company concealed inventory build-up in its surgical handpieces, selling more units than hospitals actually used, quarter after quarter, until the discrepancy became impossible to hide. On February 25, 2026, the company reported Q4 earnings and the stock dropped 18% in two days.

Here is the question the lawsuit does not answer: after management admitted the problem, fixed its sales incentives, and normalized handpiece volumes back to procedure levels, does the underlying business actually work?

The numbers from the past six quarters say it does. The numbers from the income statement say profitability is still years away. That gap is what matters for anyone thinking about this stock.

What happened — and why the 18% drop was a lagging indicator

PROCEPT makes the AquaBeam (now branded Hydros) robotic system for treating benign prostatic hyperplasia, the enlarged prostate condition that affects millions of men. The business model has two revenue streams: system sales to hospitals, roughly $485,000 per unit, and consumable handpieces that get used during each procedure and must be repurchased. The recurring handpiece revenue is where the margin and the story live.

The problem was in the recurring revenue. Management historically encouraged hospitals to buy handpieces ahead of actual procedure volume — often through end-of-quarter purchasing incentives. Handpiece sales exceeded procedure volumes by approximately 8% to 16% every quarter starting in early 2023. The gap widened. By the time the truth came out, there were more than 10,000 excess units in cumulative field inventory, already sold to hospitals but not yet used in procedures.

In Q4 2025, management cut the incentives, forced a correction, and watched quarterly handpiece sales plummet from 13,225 units in Q3 to 9,400 units in Q4 — a nearly 30% sequential drop. Q4 revenue came in at $76.4 million, missing annual guidance by tens of millions. The stock fell from $27.84 to $22.69 over two days.

That was February. The drop was not a new risk. It was the old problem clearing out of the system.

The normalization is already visible in the data

By Q1 2026, handpiece sales tracked at approximately 95% of U.S. procedures — roughly 95% of the 12,200 procedures performed that quarter. Management expected handpiece sales and procedure volumes to be "closely aligned" and the data confirms it. The old pattern of systematically overstocking hospitals has stopped.

Pricing improved at the same time. The handpiece average selling price rose from $3,340 in Q4 2025 to approximately $3,500 in Q1 2026, a 5% sequential increase that has held. Q1 2026 total revenue came in at $83.1 million, up 20% year-over-year. Q2 2026 U.S. handpiece and consumable revenue was $48.4 million, up 12% year-over-year.

Growth has not stopped. It just looks different now — less padded, less incentive-driven, and anchored to actual procedures instead of supply closet stocking.

Procedure growth remains the engine. The company's U.S. install base reached 765 systems as of Q1 2026, up 40% year-over-year. Full-year 2026 guidance calls for U.S. procedure growth of 39% to 48%, with total revenue between $390 million and $410 million — 27% to 33% growth over the $308.1 million full year 2025.

That guidance was set after the correction, not before it. It already prices in the lower handpiece volumes but higher per-unit pricing.

The profitability gap is where the real risk lives

Revenue growth of 27% to 33% on a normalized base is a strong operating number. But it tells you nothing about whether this company can stop bleeding cash.

Operating margin for the trailing twelve months is negative 33.86%. ROIC sits at negative 27.59%. Free cash flow over the past year was negative $84.9 million. The company expects an adjusted EBITDA loss of $17 million to $30 million for all of 2026, with operating expenses running approximately $350 million against $390 million to $410 million in revenue.

In other words, for every dollar of revenue, PROCEPT is spending roughly $0.85 to $0.90 on operating costs alone, before interest, taxes, or capital expenditures. Gross margin is solid at approximately 65%, but the operating margin gap — the space between gross profit and the bottom line — is enormous.

That gap is the investment question. Revenue growth without a credible path to operating leverage is a treadmill. The company is spending nearly as much to run the business as it brings in, and it has been doing so for years.

The balance sheet gives them time

This is not a company at risk of running out of money. Cash and equivalents sit at $227.9 million. Total debt is $139.3 million. Net debt is negative $176.2 million. The current ratio is 654.7%.

At a TTM burn rate of roughly $85 million in free cash flow, the cash balance covers more than two years of operations even if revenue flatlined. The real scenario — 27% to 33% growth with operating expenses held around $350 million — pushes the adjusted EBITDA loss toward the $17 million low end of guidance, meaning the burn rate should decelerate through 2026.

No dilution event is imminent. The balance sheet is a strength, not a feature that masks weakness. It simply gives management three to four years to close the operating margin gap before shareholders need to worry about equity raises.

Where does it sit against peers?

PROCEPT trades at a market cap of $1.1 billion, or approximately 3.3 times trailing sales. Intuitive Surgical — the surgical robotics category leader — trades at 12.6 times sales and 44 times earnings, with a $139 billion market cap. Hologic, a broader med device company with urology exposure, trades at a market cap of roughly $14.6 billion.

PROCEPT looks cheap relative to those names. But the comparison is between a profitable, mature category leader and a company that loses money on nearly every dollar of revenue. A low P/S ratio is not a value signal when the denominator is revenue that does not yet cover costs. It is only interesting if the operating margin gap closes — and the data from the last two quarters has not yet shown that closing.

AInvest's aggregate signal labels PRCT as a Hold, with a composite rating of 3.11 and a fundamental rating of 1.2, reflecting the revenue growth offset by profitability concerns. The technical picture reinforces caution: the stock trades below its 50-day ($20.15) and 200-day ($25.62) moving averages, with an RSI of 42, and is down 38.65% year-to-date and 48.5% over the trailing twelve months.

What the factor stack says to do

The growth factor is the clear strength. Revenue up 22.7% year-over-year, gross margin at 64.2%, U.S. procedure growth of 39% to 48% expected — this is a company where demand is real and expanding. The handpiece normalization means that growth is now tied to procedures, not supply chain distortion. That matters.

The profitability factor is where the rating collapses. Negative 33.9% operating margin and negative 27.6% ROIC are not "temporary" numbers that will resolve through incremental margin improvements. They are structural — the company's cost structure has not been proven against scale. Operating expenses of $350 million on $400 million in revenue mean the entire $50 million gap between revenue and OpEx has to convert to profit before this stock earns a profitability grade above D-.

Valuation at 3.3x sales is neither cheap nor expensive in isolation. It is the price the market assigns to a high-growth med device company that has not yet demonstrated it can grow into profitability. If the operating margin gap narrows by even 5 percentage points in 2027, the current price looks aggressive. If it does not, the P/S multiple can compress further without any additional negative news.

Momentum is broken. Down nearly 39% year-to-date, below both key moving averages, with an RSI in the 42 range. The stock is in a downtrend and the factor stack offers no reason to expect a reversal on timing grounds alone.

The portfolio role for this stock right now is watch list, not watch and buy. The procedure growth story is credible. The balance sheet is strong. The lawsuit is a lagging indicator of a commercial problem that has already been corrected. But the operating margin gap has not moved in a meaningful direction yet, and the technical picture is against any near-term entry.

The trigger that would change this from watch to add is not another quarter of revenue growth — the market already expects that. It is a sequential improvement in operating margin that proves the $350 million in operating expenses is not a fixed cost but one that scales below revenue growth. When that number appears, the P/S multiple stops being a discount and starts being a setup. Until then, the stock is a good story with an unfinished financial picture, and the distance between those two things is where the risk lives.